REGENXBIO Inc. (RGNX) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
InMode (INMD) Q1 2026: North America Drives 5% Growth as Gross Margin Narrows to 75%
May 14, 2026
-
Regenxbio (RGNX) Q4 2025: $100M Milestone Unlock Signals Commercial Readiness Amid Pipeline Catalysts
March 05, 2026
-
Regenexx Bio (RGNX) Q3 2025: RGX202 Pivotal Trial Enrollment Completes Early, Accelerating Path to 2026 Filing
November 06, 2025
-
RegeneX Bio (RGNX) Q2 2025: $100M Milestone Fuels Dual Pivotal Launches in Gene Therapy Pipeline
August 07, 2025
-
RegenxBio (RGNX) Q1 2025: $110M Upfront Fuels Pipeline as RGX202 Trial Surpasses 50% Enrollment
July 07, 2025